leisure time -WSS

leisure time

author：fashion 2025-09-03 14:39:56 - browse：71618

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Zyn nicotine pouches become unlikely player in latest culture war

WSS

Medicare Advantage insurers face 0.2% cut to 2025 payments

Biogen walks away from Aduhelm, years after polarizing approval

Zyn nicotine pouches become unlikely player in latest culture war

Democrats decry new health bill for going easy on private equity

Health Care Service Corp to buy Cigna Medicare Advantage plans

https://cbu01.alicdn.com/img/ibank/2016/307/993/3442399703_34732133.220x220xz.jpg

entertainment

leisure time

entertainment

BioMarin wins approval for gene therapy to treat hemophilia A

Philips to halt sales of sleep apnea machines in U.S.

Medicare details structure of new drug price negotiation program

Merck, Johnson & Johnson CEOs will testify on high drug prices

Medicare proposal to cover medical devices draws a mixed reaction

Biogen walks away from Aduhelm, years after polarizing approval

Drug repurposing or repositioning? The language matters

Rise in cancer among younger people worries and puzzles doctors

Medicare proposal to cover medical devices draws a mixed reaction

Bernie Sanders is gearing up to subpoena pharma CEOs

hotspot

New Alzheimer's drugs heat up race for early detection blood tests

Biogen says it will cut costs by $700 million, slash 1,000 jobs

The haunting brain science of long Covid

Pancreatic cancer early detection could be helped by AI

Health Care Service Corp to buy Cigna Medicare Advantage plans

Medicare Advantage insurers face 0.2% cut to 2025 payments

focus

leisure time

entertainment

Wikipedia